Phase I Clinical Trial of NH130 and the Prediction of Its Pharmacokinetics Using ... - Frontiers

Phase I clinical trial of NH130, a selective serotonin 5-HT2A inverse agonist for Parkinson's disease psychosis, showed favorable pharmacokinetics and safety in healthy volunteers, with no serious adverse events reported. A physiologically based pharmacokinetic model accurately predicted NH130's behavior, supporting its potential as a therapeutic agent for Parkinson's disease psychosis.